New York Genome Center

Applications are now OPEN for the New York Genome Center's Early Career Development (post-bacc training) Program!

Genetic Alliance is thrilled to announce two more iHope laboratory partners: New York Genome Center and Mendelics! Working with CHEO/The Hospital for Sick Children these labs will allow us to bring genomic testing to hundreds of children across the globe just this year, with plans for further expansion in 2025. I am grateful to the leadership at all three institutions, but particularly Kym Boycott, Christian Marshall, Vaidehi Jobanputra, PhD, FACMG and David Schlesinger for making this world-class network of genomic testing providers a reality. Read more about the partnership with NYGC and Mendelics here: https://lnkd.in/g3U8T75t https://lnkd.in/gBBCjAxE And about iHope here: https://lnkd.in/ga7t9TvG

Researchers from grantee New York Genome Center have worked with partners to develop an unprecedented AI system for detecting tumor DNA in the blood.

Mark your calendars! Applications will open August 15th for the New York Genome Center’s second annual Early Career Development (post-baccalaureate training) Program! The program provides recent undergraduates with exceptional scientific training and research experience in faculty and non-faculty laboratories, leveraging NYGC’s unique scientific strengths in genomics, computational biology, technology innovation, and clinical genetic testing. Click here for more information: https://bit.ly/3WH8DmJ

Congratulations to Gamze Gürsoy on being honored as a Herbert and Florence Irving Scholar for the 2024-2027 cohort! Irving Scholars are selected on the basis of research proposals that reflect independent, well-developed scientific initiative in clinical investigation. Gürsoy’s project title is “Overcoming Privacy Challenges in Machine Learning for Healthcare.” https://bit.ly/4c2JO9g

Molecular Diagnostic laboratory at the New York Genome Center has partnered with the iHope Genetic Health (iGH) initiative to offer pro bono genetic testing for undiagnosed children in under-resourced communities in low-to middle-income countries. This collaboration signifies a significant advancement in the expansion of the iGH network, strengthening the program's ability to create a worldwide influence. #GeneticHealth #HealthcareAccess #GlobalImpact #genomesequencing #raredisease

Congratulations to Tuuli Lappalainen, PhD, on her election to the EMBO! Dr. Lappalainen joins a network of more than 2,000 world-class researchers from Europe and beyond. Read more here: https://bit.ly/3zwC1Tr

In a study led by grantees New York Genome Center and Memorial Sloan Kettering Cancer Center, a new AI-powered method for detecting tumor DNA in blood has shown unprecedented sensitivity in predicting cancer recurrence.

An artificial intelligence-powered method for detecting tumor DNA in blood has shown unprecedented sensitivity in predicting cancer recurrence, according to a new study. The new technology can potentially improve cancer care by detecting cancer recurrence very early and improving the monitoring of tumor response to therapy. In the study, a team led by Dr. Dan Landau of Weill Cornell Medicine and NewYork-Presbyterian Hospital showed that they could train a machine learning model, a type of artificial intelligence platform, to detect circulating tumor DNA (ctDNA) based on DNA sequencing data from patient blood tests, with very high sensitivity and accuracy. The team, which included researchers from the New York Genome Center and Memorial Sloan Kettering Cancer Center, made successful demonstrations of the technology when tested with data from patients with lung cancer, melanoma, breast cancer, colorectal cancer and precancerous colorectal polyps. https://bit.ly/45pXCJ3